TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35357767

Group type: EXPERIMENTAL
Intervention: HIV pre-exposure prophylaxis (PrEP)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: HCV-positive participants
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: HCV-negative participants
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Early PrEP adopters
Number of subjects: 599
Study: 35357903

Group type: EXPERIMENTAL
Intervention: HIPEC with cisplatin during optimal cytoreductive surgery (CRS)
Number of subjects: 35
Study: 35358290

Group type: EXPERIMENTAL
Intervention: Leronlimab (350 mg or 700 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Leronlimab (50 mg/kg)
Number of subjects: 9
Study: 35358443

Group type: EXPERIMENTAL
Intervention: Index therapies included immunochemotherapy (n=133)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Index therapies included anti-CD20 antibody monotherapy (n=53)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Index therapies included lenalidomide with or without anti-CD20 (n=37)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Index therapies included phosphoinositide 3-kinase inhibitors with or without anti-CD20 (n=25)
Number of subjects: 441
Study: 35358442

Group type: EXPERIMENTAL
Intervention: FMA reduced-intensity conditioned HSCT
Number of subjects: 249
Study: 35358810

Group type: EXPERIMENTAL
Intervention: Baseline phenotypic measurements (e.g., patient global estimate of health status, 6-min walk distance, HRQoL measures)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-min walk distance cutoff
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HRQoL measure cutoffs
Number of subjects: 0
Study: 35358904

Group type: EXPERIMENTAL
Intervention: Anisocytosis (RDW > 14.5) in Cohort 1
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: RDW in Cohort 1
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: RDW in Cohort 2
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Anisocytosis and myocardial fibrosis in both cohorts
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Elevated RDW in both cohorts
Number of subjects: 360
Study: 35358998

Group type: EXPERIMENTAL
Intervention: Activated tumor cells (10-gene signature)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Presence of T-cell inflamed microenvironment in LN
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clonal evolution
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Single-cell RNA sequencing (scRNA-seq)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: RNA velocity analysis
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Whole exome sequencing (WES)
Number of subjects: 34
Study: 35359000

Group type: EXPERIMENTAL
Intervention: Atezolizumab (atezo) with obinutuzumab (G) and bendamustine
Number of subjects: 40
Study: 35359139

Group type: EXPERIMENTAL
Intervention: Preoperative perfusion index (PI)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Preoperative plethysmographic variability index (PVI)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Baseline dicrotic plethysmography (Dicpleth)
Number of subjects: 95
Study: 35359899

Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (IMP) - Molecular radiotherapy (details on dosage and duration not available)
Number of subjects: 0
Study: 35360218

Group type: EXPERIMENTAL
Intervention: ICP-directed treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (patients treated at another ward)
Number of subjects: 68
Study: 35360224

Group type: EXPERIMENTAL
Intervention: Autonomic Regulation Therapy (ART) using chronic vagus nerve stimulation (VNS)
Number of subjects: 15
Study: 35360431

Group type: EXPERIMENTAL
Intervention: ICTP block (T2 TPVB supplemented with IC block)
Number of subjects: 80

Group type: COMPARATOR
Intervention: IC block (combined interscalene brachial plexus with superficial cervical plexus block)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ICTP block
Number of subjects: 80

Group type: COMPARATOR
Intervention: IC block
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil (rescue anesthesia)
Number of subjects: 80
Study: 35360522

Group type: EXPERIMENTAL
Intervention: R3-AFP score including last available pre-LT AFP value
Number of subjects: 2444

Group type: COMPARATOR
Intervention: R3 model without AFP
Number of subjects: 2444
Study: 35360736

Group type: EXPERIMENTAL
Intervention: Alpha variant (B.1.1.7)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Beta variant (B.1.351)
Number of subjects: 333
Study: 35360744

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescents
Number of subjects: 0
Study: 35360928

Group type: EXPERIMENTAL
Intervention: ANA catheter system combined with stent retriever
Number of subjects: 74
Study: 35360980

Group type: EXPERIMENTAL
Intervention: Upper limb difference (including thumb hypoplasia)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bilateral upper limb differences
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Age at diagnosis
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Late diagnosis of limb anomalies
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Screening for FA
Number of subjects: 48
Study: 35361107

Group type: EXPERIMENTAL
Intervention: Ventricular tachyarrhythmias (VTA) due to coronary artery disease (CAD) requiring percutaneous coronary intervention (PCI) in young adults.
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Idiopathic VTA in young adults.
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: VTA associated with underlying channelopathies in young adults.
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: VTA associated with primary cardiomyopathies in young adults.
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: VTA associated with acute myocardial infarction (AMI) in young adults.
Number of subjects: 259

Group type: COMPARATOR
Intervention: VTA associated with acute myocardial infarction (AMI) in adults.
Number of subjects: 259

Group type: COMPARATOR
Intervention: Idiopathic VTA in adults.
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation (CPR) in all patients.
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF) < 35% in young adults.
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: All-cause mortality in young adults and adults.
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Survival rates at index hospitalization and after 2.5 years for young adults and adults.
Number of subjects: 259
Study: 35361185

Group type: EXPERIMENTAL
Intervention: Physical therapy aimed at stabilizing the hip joint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arthroscopic plication of the hip joint capsule
Number of subjects: 0
Study: 35361224

Group type: EXPERIMENTAL
Intervention: Adapted classification criteria for migraine and CH
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Strict application of ICHD-3 criteria
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ignoring episodic TTH classifications
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Knowledge-based system for headache trigger detection
Number of subjects: 18
Study: 35361350

Group type: COMPARATOR
Intervention: Stage I (normal renal function)
Number of subjects: 10354

Group type: EXPERIMENTAL
Intervention: Stage III (moderate dysfunction)
Number of subjects: 10354

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 10354

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 10354
Study: 35361478

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) concentration
Number of subjects: 978

Group type: EXPERIMENTAL
Intervention: Gradient boosting model for detection of CAD
Number of subjects: 978
Study: 35361487

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg administered intravenously Q3W for up to 35 cycles (approximately 2 years)
Number of subjects: 101
Study: 35361490

Group type: EXPERIMENTAL
Intervention: SmartPilot® View (SPV)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Control (CONTROL)
Number of subjects: 493
Study: 35361684

Group type: EXPERIMENTAL
Intervention: AIEC identification within the neoterminal ileum at M6
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: AIEC identification within the surgical specimen
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: History of positive test for AIEC (M0 or M6)
Number of subjects: 181
Study: 35361691

Group type: EXPERIMENTAL
Intervention: Two-dose vaccination
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Third SARS-CoV-2 vaccine
Number of subjects: 33
Study: 35362047

Group type: EXPERIMENTAL
Intervention: CBLB-deficient CD8+ T cells
Number of subjects: 0
Study: 35362065

Group type: EXPERIMENTAL
Intervention: Addressing social determinants of health/adverse childhood experiences in primary care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training of primary care professionals and staff
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Referral processes for additional evaluation or help
Number of subjects: 0
Study: 35362192

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine
Number of subjects: 80
Study: 35362522

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral therapy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Recent IDU with needle/syringe sharing
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Longer HCV testing interval
Number of subjects: 161
Study: 35362761

Group type: EXPERIMENTAL
Intervention: In vivo imaging methods to visualize and quantify the peripheral cholinergic nervous system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total volume-of-distribution rank order
Number of subjects: 0
Study: 35362857

Group type: EXPERIMENTAL
Intervention: Steroid use in the second wave
Number of subjects: 9967

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 9967

Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 9967

Group type: EXPERIMENTAL
Intervention: Critical care admission
Number of subjects: 9967

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 9967
Study: 35362862

Group type: EXPERIMENTAL
Intervention: Low-dose estrogen/progestin (LEP)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Non-LEP treatment (NSAIDs or Chinese herbal medicines)
Number of subjects: 397
Study: 35362878

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4 capsules of 530 mg EPA, 150 mg DHA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 55

Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 55
Study: 35363144

Group type: EXPERIMENTAL
Intervention: LEAP QI training program
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard implementation (adding a link to DecisionPrecision in the electronic health record)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Academic detailing (AD)
Number of subjects: 8
Study: 35363152

Group type: EXPERIMENTAL
Intervention: Creatine and exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 30
Study: 35363252

Group type: EXPERIMENTAL
Intervention: Meal ingestion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GIP infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Meal ingestion after bariatric surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GIP infusion after bariatric surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: VAT perfusion response
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VAT perfusion response after bariatric surgery
Number of subjects: 20
Study: 35363564

Group type: EXPERIMENTAL
Intervention: Gameplay of ≥1.5 hours/day in the non-LSC traits group (higher DP group)
Number of subjects: 1535
Study: 35363623

Group type: EXPERIMENTAL
Intervention: Individualized-Targeted Computerized Cognitive Training
Number of subjects: 0
Study: 35363631

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (BFT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fecobionics
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional technologies (ARM-BET)
Number of subjects: 12
Study: 35363884

Group type: EXPERIMENTAL
Intervention: Systemic antibiotics combined with ethanol lock solution
Number of subjects: 760

Group type: COMPARATOR
Intervention: Tissue plasminogen activator (TPA) lock solution with concurrent systemic antibiotics
Number of subjects: 760

Group type: COMPARATOR
Intervention: Catheter guidewire exchange
Number of subjects: 760
Study: 35364421

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles
Number of subjects: 104
Study: 35364569

Group type: EXPERIMENTAL
Intervention: LCTOPC1 (2 × 10^6 cells) administered via intraparenchymal injection
Number of subjects: 5
Study: 35364716

Group type: EXPERIMENTAL
Intervention: Carotid vulnerable plaques coexisting with lacunes
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Carotid vulnerable plaques coexisting with moderate-to-severe WMHs
Number of subjects: 634

Group type: COMPARATOR
Intervention: Carotid vulnerable plaques
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Carotid vulnerable plaques coexisting with CSVDs
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Lacunes
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe WMHs
Number of subjects: 634
Study: 35365547

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring for 3 days every fortnight for 12 weeks postpartum
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitoring at 12 weeks postpartum
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Questionnaires completed by women and healthcare professionals regarding postpartum care and CVD risk knowledge
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of hypertension and influencing factors (severity of HDP, maternal age, BMI, ethnicity)
Number of subjects: 300
Study: 35365828

Group type: EXPERIMENTAL
Intervention: FIL200 (200 mg daily)
Number of subjects: 3691

Group type: EXPERIMENTAL
Intervention: FIL100 (100 mg daily)
Number of subjects: 3691

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 3691

Group type: EXPERIMENTAL
Intervention: FIL200
Number of subjects: 3691

Group type: EXPERIMENTAL
Intervention: FIL100
Number of subjects: 3691
Study: 35366263

Group type: EXPERIMENTAL
Intervention: Combination of nutraceuticals for 6 months as part of a Mediterranean diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 0
Study: 35366312

Group type: EXPERIMENTAL
Intervention: Iron deficiency treatment
Number of subjects: 5416

Group type: EXPERIMENTAL
Intervention: Vitamin deficiency treatment
Number of subjects: 5416

Group type: EXPERIMENTAL
Intervention: Anemia due to iron deficiency
Number of subjects: 5416

Group type: EXPERIMENTAL
Intervention: Anemia of inflammation
Number of subjects: 5416

Group type: EXPERIMENTAL
Intervention: Impact of anemia on quality of life
Number of subjects: 5416
Study: 35366378

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 142
Study: 35366432

Group type: EXPERIMENTAL
Intervention: Modified sit-up test (bedside)
Number of subjects: 53
Study: 35366570

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI/bev
Number of subjects: 1187

Group type: COMPARATOR
Intervention: doublets/bev
Number of subjects: 1187
Study: 35366613

Group type: EXPERIMENTAL
Intervention: Standard 'next-step' treatment strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific types of childhood adversities
Number of subjects: 0
Study: 35366711

Group type: EXPERIMENTAL
Intervention: Elevated blood hemoglobin (HGB > 149.5 g/L)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Normal blood hemoglobin (HGB ≤ 149.5 g/L)
Number of subjects: 800
Study: 35366805

Group type: EXPERIMENTAL
Intervention: Antiviral treatment for HBV (20.3% of patients received this treatment)
Number of subjects: 1177

Group type: COMPARATOR
Intervention: Patients without cirrhosis
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Self-withdrawal of nucleos(t)ide analog (NA)
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Age, cirrhosis at admission, and platelet level
Number of subjects: 1177
Study: 35366820

Group type: EXPERIMENTAL
Intervention: Sputum lipoarabinomannan (LAM) as a biomarker
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Sputum lipoarabinomannan (LAM)
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Sputum lipoarabinomannan (LAM) positivity
Number of subjects: 776
Study: 35366825

Group type: EXPERIMENTAL
Intervention: Preoperative accelerated partial breast irradiation (APBI) using CyberKnife, single fraction (exact dosage not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative accelerated partial breast irradiation (APBI)
Number of subjects: 0
Study: 35366848

Group type: EXPERIMENTAL
Intervention: KISS intervention (Knocking out Infections through Safer-sex and Screening)
Number of subjects: 79
Study: 35366920

Group type: EXPERIMENTAL
Intervention: L-carnitine (L-C)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 35366963

Group type: EXPERIMENTAL
Intervention: Odronextamab (up to 320 mg once per week, with maintenance every 2 weeks after cycle 4)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Odronextamab (doses of 5 mg or higher)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Odronextamab (doses of 80 mg or higher)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Odronextamab
Number of subjects: 145
Study: 35367107

Group type: EXPERIMENTAL
Intervention: Provider communication
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Gender-appropriate care
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Trauma-sensitive communication
Number of subjects: 1395
Study: 35367396

Group type: EXPERIMENTAL
Intervention: iNKT cell and PD-1+CD8+ T cell-based immunotherapy, infused every 3-5 weeks, considered 1 cycle.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: iNKT cell and PD-1+CD8+ T cell-based immunotherapy
Number of subjects: 3
Study: 35367616

Group type: EXPERIMENTAL
Intervention: Fluorescence guided photodynamic therapy (PDT) using a portable fibre-coupled LED system
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluorescence guided photodynamic therapy (PDT)
Number of subjects: 30
Study: 35367851

Group type: EXPERIMENTAL
Intervention: Automatic dose verification system with propagated contours
Number of subjects: 31
Study: 35367908

Group type: EXPERIMENTAL
Intervention: Li-Fraumeni syndrome (LFS) experiences
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Cancer screening, risk reduction, and treatment
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Family connections and shared experiences
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Objectification of the body
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Intense pain or loss experiences
Number of subjects: 117
Study: 35368221

Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream applied twice daily for 28 days, then continued on active lesions for an additional 28 days (extension period).
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream
Number of subjects: 41
Study: 35368281

Group type: EXPERIMENTAL
Intervention: Mandibular movement (MM) monitoring with machine learning analysis
Number of subjects: 31

Group type: COMPARATOR
Intervention: In-home polysomnography (PSG)
Number of subjects: 31
Study: 35368514

Group type: EXPERIMENTAL
Intervention: Training load and genotype
Number of subjects: 300
Study: 35368551

Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with dietary restriction (3 times per week for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dietary restriction only (control group)
Number of subjects: 60
Study: 35368811

Group type: EXPERIMENTAL
Intervention: Evidence-based supportive care change package consisting of 14 best-practice recommendations for kidney failure care, including systematic identification of seriously ill patients, goals-of-care conversations, and care options to respond to patient wishes.
Number of subjects: 0
Study: 35369018

Group type: EXPERIMENTAL
Intervention: p-inulin (8 g twice daily for 12 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No treatment (pretreatment phase)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: p-inulin
Number of subjects: 13
Study: 35369096

Group type: EXPERIMENTAL
Intervention: e-Diary mobile food record
Number of subjects: 365
Study: 35369374

Group type: EXPERIMENTAL
Intervention: Medications containing acid salts (Metformin hydrochloride at 2550 mg/d and Gabapentin hydrochloride at 2700 mg/d)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride (15.4 meq/d)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Gabapentin hydrochloride (13.0 meq/d)
Number of subjects: 74
Study: 35369607

Group type: EXPERIMENTAL
Intervention: Ramucirumab (10 mg/kg) plus Gefitinib (250 mg/d)
Number of subjects: 82
Study: 35369646

Group type: EXPERIMENTAL
Intervention: Arterial tortuosity index in AIS patients
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control group (83 subjects)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Tortuosity of left carotid artery system and vertebral artery
Number of subjects: 249
Study: 35369714

Group type: EXPERIMENTAL
Intervention: Receiving hospital with shared hospital affiliation
Number of subjects: 73114

Group type: EXPERIMENTAL
Intervention: Receiving hospital with teaching hospital status
Number of subjects: 73114

Group type: EXPERIMENTAL
Intervention: Receiving hospital with stroke center status
Number of subjects: 73114

Group type: EXPERIMENTAL
Intervention: Receiving hospital with same or higher reputational ranking
Number of subjects: 73114
Study: 35369854

Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccines
Number of subjects: 139

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 139
Study: 35370021

Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Focal ablation
Number of subjects: 181